Cargando…
SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
Sodium glucose cotransporters (SGLTs) are transport proteins that are expressed throughout the body. Inhibition of SGLTs is a relatively novel therapeutic strategy to improve glycemic control and has been shown to promote cardiorenal benefits. Dual SGLT1/2 inhibitors (SGLT1/2i) such as sotagliflozin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384225/ https://www.ncbi.nlm.nih.gov/pubmed/37520739 http://dx.doi.org/10.1016/j.isci.2023.107260 |
_version_ | 1785081105320247296 |
---|---|
author | Herat, Lakshini Yasaswi Matthews, Jennifer Rose Hibbs, Moira Rakoczy, Elizabeth Piroska Schlaich, Markus Peter Matthews, Vance Bruce |
author_facet | Herat, Lakshini Yasaswi Matthews, Jennifer Rose Hibbs, Moira Rakoczy, Elizabeth Piroska Schlaich, Markus Peter Matthews, Vance Bruce |
author_sort | Herat, Lakshini Yasaswi |
collection | PubMed |
description | Sodium glucose cotransporters (SGLTs) are transport proteins that are expressed throughout the body. Inhibition of SGLTs is a relatively novel therapeutic strategy to improve glycemic control and has been shown to promote cardiorenal benefits. Dual SGLT1/2 inhibitors (SGLT1/2i) such as sotagliflozin target both SGLT1 and 2 proteins. Sotagliflozin or vehicle was administered to diabetic Akimba mice for 8 weeks at a dose of 25 mg/kg/day. Urine glucose levels, water consumption, and body weight were measured weekly. Serum, kidney, pancreas, and brain tissue were harvested under terminal anesthesia. Tissues were assessed using immunohistochemistry or ELISA techniques. Treatment with sotagliflozin promoted multiple metabolic benefits in diabetic Akimba mice resulting in decreased blood glucose and improved polydipsia. Sotagliflozin also prevented mortalities associated with diabetes. Our data suggests that there is the possibility that combined SGLT1/2i may be superior to SGLT2i in controlling glucose homeostasis and provides protection of multiple organs affected by diabetes. |
format | Online Article Text |
id | pubmed-10384225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103842252023-07-30 SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes Herat, Lakshini Yasaswi Matthews, Jennifer Rose Hibbs, Moira Rakoczy, Elizabeth Piroska Schlaich, Markus Peter Matthews, Vance Bruce iScience Article Sodium glucose cotransporters (SGLTs) are transport proteins that are expressed throughout the body. Inhibition of SGLTs is a relatively novel therapeutic strategy to improve glycemic control and has been shown to promote cardiorenal benefits. Dual SGLT1/2 inhibitors (SGLT1/2i) such as sotagliflozin target both SGLT1 and 2 proteins. Sotagliflozin or vehicle was administered to diabetic Akimba mice for 8 weeks at a dose of 25 mg/kg/day. Urine glucose levels, water consumption, and body weight were measured weekly. Serum, kidney, pancreas, and brain tissue were harvested under terminal anesthesia. Tissues were assessed using immunohistochemistry or ELISA techniques. Treatment with sotagliflozin promoted multiple metabolic benefits in diabetic Akimba mice resulting in decreased blood glucose and improved polydipsia. Sotagliflozin also prevented mortalities associated with diabetes. Our data suggests that there is the possibility that combined SGLT1/2i may be superior to SGLT2i in controlling glucose homeostasis and provides protection of multiple organs affected by diabetes. Elsevier 2023-07-03 /pmc/articles/PMC10384225/ /pubmed/37520739 http://dx.doi.org/10.1016/j.isci.2023.107260 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Herat, Lakshini Yasaswi Matthews, Jennifer Rose Hibbs, Moira Rakoczy, Elizabeth Piroska Schlaich, Markus Peter Matthews, Vance Bruce SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title | SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title_full | SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title_fullStr | SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title_full_unstemmed | SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title_short | SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
title_sort | sglt1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384225/ https://www.ncbi.nlm.nih.gov/pubmed/37520739 http://dx.doi.org/10.1016/j.isci.2023.107260 |
work_keys_str_mv | AT heratlakshiniyasaswi sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes AT matthewsjenniferrose sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes AT hibbsmoira sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes AT rakoczyelizabethpiroska sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes AT schlaichmarkuspeter sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes AT matthewsvancebruce sglt12inhibitionimprovesglycemiccontrolandmultiorganprotectionintype1diabetes |